180 related articles for article (PubMed ID: 30926650)
1. Recombinant α
Andersson CK; Shubbar E; Schüler E; Åkerström B; Gram M; Forssell-Aronsson EB
J Nucl Med; 2019 Nov; 60(11):1600-1604. PubMed ID: 30926650
[TBL] [Abstract][Full Text] [Related]
2. Hedgehog inhibitor sonidegib potentiates
Spetz J; Langen B; Rudqvist N; Parris TZ; Helou K; Nilsson O; Forssell-Aronsson E
BMC Cancer; 2017 Aug; 17(1):528. PubMed ID: 28789624
[TBL] [Abstract][Full Text] [Related]
3.
Kristiansson A; Örbom A; Ahlstedt J; Karlsson H; Zedan W; Gram M; Åkerström B; Strand SE; Altai M; Strand J; Vilhelmsson Timmermand O
Biomolecules; 2021 Feb; 11(2):. PubMed ID: 33579037
[TBL] [Abstract][Full Text] [Related]
4. Peptide Receptor Radionuclide Therapy with
Cullinane C; Jeffery CM; Roselt PD; van Dam EM; Jackson S; Kuan K; Jackson P; Binns D; van Zuylekom J; Harris MJ; Hicks RJ; Donnelly PS
J Nucl Med; 2020 Dec; 61(12):1800-1805. PubMed ID: 32414949
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models.
Dalm SU; Nonnekens J; Doeswijk GN; de Blois E; van Gent DC; Konijnenberg MW; de Jong M
J Nucl Med; 2016 Feb; 57(2):260-5. PubMed ID: 26514177
[TBL] [Abstract][Full Text] [Related]
6. Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment.
Sandström M; Garske-Román U; Granberg D; Johansson S; Widström C; Eriksson B; Sundin A; Lundqvist H; Lubberink M
J Nucl Med; 2013 Jan; 54(1):33-41. PubMed ID: 23223392
[TBL] [Abstract][Full Text] [Related]
7. Time-dependent transcriptional response of GOT1 human small intestine neuroendocrine tumor after
Spetz J; Rudqvist N; Langen B; Parris TZ; Dalmo J; Schüler E; Wängberg B; Nilsson O; Helou K; Forssell-Aronsson E
Nucl Med Biol; 2018 May; 60():11-18. PubMed ID: 29502008
[TBL] [Abstract][Full Text] [Related]
8. Co-administration with A1M does not influence apoptotic response of
Rassol N; Andersson C; Pettersson D; Al-Awar A; Shubbar E; Kovács A; Åkerström B; Gram M; Helou K; Forssell-Aronsson E
Sci Rep; 2023 Apr; 13(1):6417. PubMed ID: 37076494
[TBL] [Abstract][Full Text] [Related]
9. Recombinant α
Alattar AG; Kristiansson A; Karlsson H; Vallius S; Ahlstedt J; Forssell-Aronsson E; Åkerström B; Strand SE; Flygare J; Gram M
Biomolecules; 2023 Jun; 13(6):. PubMed ID: 37371508
[No Abstract] [Full Text] [Related]
10. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog
Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X
J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971
[TBL] [Abstract][Full Text] [Related]
11. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.
De Jong M; Valkema R; Jamar F; Kvols LK; Kwekkeboom DJ; Breeman WA; Bakker WH; Smith C; Pauwels S; Krenning EP
Semin Nucl Med; 2002 Apr; 32(2):133-40. PubMed ID: 11965608
[TBL] [Abstract][Full Text] [Related]
12. Protection of Kidney Function with Human Antioxidation Protein α
Kristiansson A; Ahlstedt J; Holmqvist B; Brinte A; Tran TA; Forssell-Aronsson E; Strand SE; Gram M; Åkerström B
Antioxid Redox Signal; 2019 May; 30(14):1746-1759. PubMed ID: 29943622
[TBL] [Abstract][Full Text] [Related]
13. Personalized
Del Prete M; Buteau FA; Beauregard JM
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1490-1500. PubMed ID: 28361189
[TBL] [Abstract][Full Text] [Related]
14. Transcriptional effects of
Spetz J; Langen B; Rudqvist NP; Parris TZ; Shubbar E; Dalmo J; Wängberg B; Nilsson O; Helou K; Forssell-Aronsson E
EJNMMI Res; 2019 Mar; 9(1):28. PubMed ID: 30895393
[TBL] [Abstract][Full Text] [Related]
15. Neuroblastoma xenograft models demonstrate the therapeutic potential of
Romiani A; Spetz J; Shubbar E; Lind DE; Hallberg B; Palmer RH; Forssell-Aronsson E
BMC Cancer; 2021 Aug; 21(1):950. PubMed ID: 34433438
[TBL] [Abstract][Full Text] [Related]
16. Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT?
Esser JP; Krenning EP; Teunissen JJ; Kooij PP; van Gameren AL; Bakker WH; Kwekkeboom DJ
Eur J Nucl Med Mol Imaging; 2006 Nov; 33(11):1346-51. PubMed ID: 16847654
[TBL] [Abstract][Full Text] [Related]
17. The amount of injected 177Lu-octreotate strongly influences biodistribution and dosimetry in C57BL/6N mice.
Schüler E; Österlund A; Forssell-Aronsson E
Acta Oncol; 2016; 55(1):68-76. PubMed ID: 25813472
[TBL] [Abstract][Full Text] [Related]
18. Priming increases the anti-tumor effect and therapeutic window of
Dalmo J; Spetz J; Montelius M; Langen B; Arvidsson Y; Johansson H; Parris TZ; Helou K; Wängberg B; Nilsson O; Ljungberg M; Forssell-Aronsson E
EJNMMI Res; 2017 Dec; 7(1):6. PubMed ID: 28097640
[TBL] [Abstract][Full Text] [Related]
19. [177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy.
de Jong M; Breeman WA; Bernard BF; Bakker WH; Schaar M; van Gameren A; Bugaj JE; Erion J; Schmidt M; Srinivasan A; Krenning EP
Int J Cancer; 2001 Jun; 92(5):628-33. PubMed ID: 11340564
[TBL] [Abstract][Full Text] [Related]
20. Comparison of [177Lu-DOTA0,Tyr3]-octreotate and [177Lu-DOTA0,Tyr3]-octreotide for receptor-mediated radiation therapy of the xenografted human midgut carcinoid tumor GOT1.
Swärd C; Bernhardt P; Johanson V; Schmitt A; Ahlman H; Stridsberg M; Forssell-Aronsson E; Nilsson O; Kölby L
Cancer Biother Radiopharm; 2008 Feb; 23(1):114-20. PubMed ID: 18298335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
